Baird Capital approaches sale of Prescient Healthcare Group

A deal is said to be imminent, with Bridgepoint expected to invest in the biopharma strategy consulting business through Bridgepoint Development Capital, its lower mid-cap fund.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this